secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001193805-25-001357
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Immunic presents positive vidofludimus calcium data at ECTRIMS, showing disability improvement in progressive MS
--------------------------------------------------------------------------------

- Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.
- Treatment reduced risk of 24-week confirmed disability worsening by 23.8% overall and 33.7% in patients without baseline Gd+ lesions.
- Long-term EMPhASIS open-label extension data showed 92.7% of RRMS patients remained free of 24-week confirmed disability worsening at 144 weeks.
- Preclinical EAE models demonstrated reduced T cell infiltration and increased neuroprotective markers with vidofludimus calcium.
- Data from four poster presentations and one oral presentation highlighted Nurr1 activation as a novel neuroprotective mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/0001193805-25-001357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/e664856_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer